• Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
  • Facebook
  • LinkedIn
  • Twitter
  • Vimeo
Home
Research areas
    ADME-Tox
    Biomarkers
    Cell Biology and Signalling
    Cell Sourcing - Cell Culture Technologies
    Drug Discovery
    Gene Expression - Molecular Biology
    Stem Cells
    Supplying Discovery Tools
Contact us
Meet the authors
Tebubio's blog - Acting and reacting in life sciences and biotechnologies
  • Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
Supplying Discovery Tools

Why and how to inhibit proteases?

25/02/2016 by Ali El Baya, PhD 1 Comment

There are approximately 600 proteases encoded by the human genome; countless others are produced by other animals, plants, bacteria, viruses, and yeast.

As proteases are involved in all kind of cell biological processes and play a role in a huge number of diseases, protease inhibitors are commonly used tools in essentially every Life Science laboratory.

What are the fields of applications for protease inhibitors?

Often protease inhibitors are used as simple tools to protect proteins from proteolytical degradation during protein purification or cell/tissue extract preparation. These can be standalone inhibitors or mixtures. Members of this group of nonspecific inhibitors (Leupeptin, Pepstatin A, etc.) are combined to target all protease categories: aspartic, serine, cysteine, threonine, thermolysin-like proteases, metalloproteases, and aminopeptidases.

Continue reading
Biomarkers

Find metastatic biomarkers in osteosarcoma!

by Ana Arraztio No Comments

Early in 2015, researchers of The University of Queensland Diamantina Institute (Australia) have shown a very sensible approach to the discovery of new biomarkers associated to transition from non-metastatic tumours to metastatic tumours in osteosarcoma. Not to be a spoiler, but they found that the uPA/uPAR axis is crucial for this, and can be used as a prognostic biomarker. In fact, inhibition of this axis can inhibit the metastasis in this type of tumours. (Endo-Muñoz et al. DOI: 10.1371/journal.pone.0133592).

journal.pone.0133592.g006

Model of uPA/uPAR signaling in osteosarcoma and the bone microenvironment. Source: Liliana Endo-Munoz; DOI: 10.1371/journal.pone.0133592.

I don’t want to focus on the biomarker per se, but rather, on the process that this lab followed to discover this new biomarker.

Continue reading

Most popular posts

  • HeLa cells: Origin of this important cell line in life science research
  • How to choose the perfect buffer to get a pure, stabilised, functional protein
  • From RUO to IVD - the acronym guide to reagents' intended use
My Tweets

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Copyright © 2018 - tebu-bio - visit our main website at tebu-bio.com

 

Loading Comments...